Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Lentiviral Vector Contract Development Manufacturing Organizations Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Lentiviral Vector Contract Development Manufacturing: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.4. COVID-19 Impact Analysis
Chapter 4. Lentiviral Vector Contract Development Manufacturing Organizations Market: Workflow Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Lentiviral Vector Contract Development Manufacturing Organizations Market Share, 2022 & 2030
4.3. Segment Dashboard
4.4. Global Lentiviral Vector Contract Development Manufacturing Organizations Market by Workflow Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Upstream
4.5.1.1. Upstream market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2. Adherent market, 2018- 2030 (USD Million)
4.5.1.3. Suspension, 2018- 2030 (USD Million)
4.5.2. Downstream
4.5.2.1. Downstream Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Lentiviral Vector Contract Development Manufacturing Organizations Market: End Use Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Lentiviral Vector Contract Development Manufacturing Organizations Market Share, 2022 & 2030
5.3. Segment Dashboard
5.4. Global Lentiviral Vector Contract Development Manufacturing Organizations Market by End Use Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Pharmaceutical & Biopharmaceutical Companies
5.5.1.1. Pharmaceutical & biopharmaceutical Companies Market estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Academic and Research Institutes
5.5.2.1. Academic and Research Insitutes Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Lentiviral Vector Contract Development Manufacturing Organizations Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2022 & 2030
6.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. Market estimates and forecast, 2018 - 2030 (Value)
6.3.2. U.S.
6.3.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.3.3. Canada
6.3.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.2. Germany
6.4.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.3. France
6.4.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.4. Italy
6.4.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.5. Spain
6.4.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.6. Denmark
6.4.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.7. Sweden
6.4.7.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.4.8. Norway
6.4.8.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecast, 2018 - 2030 (USD Billion, Volume, Thousand)
6.5.2. China
6.5.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.5.3. India
6.5.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.5.4. Australia
6.5.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.5.5. Thailand
6.5.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.5.6. South Korea
6.5.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.6.2. Mexico
6.6.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.6.3. Argentina
6.6.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7.3. UAE
6.7.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
Chapter 7. Competitive Landscape
7.1. Company Profiles
7.1.1. Thermo Fischer Scientific, inc.
7.1.1.1. Company overview
7.1.1.2. Financial Performance
7.1.1.3. Product benchmarking
7.1.1.4. Strategic initiatives
7.1.2. Oxford Biomedica
7.1.2.1. Company overview
7.1.2.2. Financial performance
7.1.2.3. Product benchmarking
7.1.2.4. Strategic initiatives
7.1.3. Charles River Laboratories International, Inc.
7.1.3.1. Company overview
7.1.3.2. Financial performance
7.1.3.3. Product benchmarking
7.1.3.4. Strategic initiatives
7.1.4. Creative Biogene
7.1.4.1. Company overview
7.1.4.2. Financial performance
7.1.4.3. Product benchmarking
7.1.4.4. Strategic initiatives
7.1.5. GeneScript ProBio
7.1.5.1. Company overview
7.1.5.2. Financial performance
7.1.5.3. Product benchmarking
7.1.5.4. Strategic initiatives
7.1.6. Merk KGaA
7.1.6.1. Company overview
7.1.6.2. Financial performance
7.1.6.3. Product benchmarking
7.1.6.4. Strategic initiatives
7.1.7. Catalent Inc.
7.1.7.1. Company overview
7.1.7.2. Financial performance
7.1.7.3. Product benchmarking
7.1.7.4. Strategic initiatives
7.1.8. Ask Bio
7.1.8.1. Company overview
7.1.8.2. Financial performance
7.1.8.3. Product benchmarking
7.1.8.4. Strategic initiatives
7.1.9. Lonza
7.1.9.1. Company overview
7.1.9.2. Financial performance
7.1.9.3. Product benchmarking
7.1.9.4. Strategic initiatives
7.1.10. Curia Global Inc.
7.1.10.1. Company overview
7.1.10.2. Financial performance
7.1.10.3. Product benchmarking
7.1.10.4. Strategic initiatives